RBC Europe’s Celldex Therapeutics CLDX Stock Holding History

RBC Europe’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-400	Closed	-$3.02K	–	1138
2018 Q2	$3.02K	Hold	400	–	–	﹤0.01%	1028
2018 Q1	$14K	Hold	400	–	–	﹤0.01%	751
2017 Q4	$17K	Buy	+400	New	+$17.1K	﹤0.01%	723

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

RBC Europe's CLDX Position: Q3 2018 in Review

RBC Europe sold out of Celldex Therapeutics (CLDX) in Q3 2018, closing a stake of 400 shares — an estimated $3.02K sold.

RBC Europe first reported a position in CLDX in Q4 2017 and held it in 3 quarters. The position peaked at $17K in Q4 2017. 95 funds tracked by Wall St. Rank hold CLDX as of Q3 2018.

RBC Europe reported no remaining Celldex Therapeutics position as of Q3 2018 after selling out during the quarter.
RBC Europe sold 400 Celldex Therapeutics shares in Q3 2018, an estimated $3.02K.
RBC Europe first reported a position in Celldex Therapeutics in Q4 2017 and held it in 3 quarters.
RBC Europe's Celldex Therapeutics position peaked at $17K in Q4 2017.
95 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2018.

Based on RBC Europe's 13F filing for Q3 2018, filed 9 Nov 2023.